Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of NMS-03597812 in Relapsed/Refractory Multiple Myeloma
NCT05027594Phase 1Terminated
- Sponsor
- Nerviano Medical Sciences
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NMS-03597812 in multiple myeloma (MM) (3 arms), sponsored by Nerviano Medical Sciences. Primary endpoint: Number of Participants with first-cycle dose limiting toxicity. Started Sep 2022; status: terminated.
02
Drugs
NMS-03597812
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05027594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027594.